Oncologie clinique : rapports de cas

Pembrolizumab Associated Pericardial Effusion In A Patient With Advanced Esophageal Cancer

Akesh Thomas, Emmitt Lee Turner, Lawrence Sevilla Parwan and Sajin M Karakattu

Pembrolizumab is an Immune Checkpoint Inhibitor (ICI) that exerts anti-tumor activity by inhibiting the interaction of programmed cell death protein 1 with its ligand (PD-L1) on activated lymphocytes.Immune Related adverse effects are a major concern for the use of ICI. We are reporting the case of a 64 year old white male with advanced esophageal adenocarcinoma who presented with moderate pericardial effusion after receiving treatment with pembrolizumab. The patient was treated with systemic steroids which improved his condition. Clinicians should consider the possibility of Immure related adverse effects in patients receiving immunotherapy with a wide array of presentations.